Barbara O’Brien, MD, discussed findings and implications from the phase 2 TBCRC049 study evaluating the combination of ...

Bile duct cancer is rare, treatment options are limited, and the survival rates are low ... breast cancer with high levels of HER2 expression (known as HER2-positive). In the new trial of ...

In terms of progression-free survival ... 66% in terms of an intracranial response rate is very high and really the highest ...

The biggest increase in 2-year survival associated with Medicaid expansion was among patients with stage III disease, with a ...

An early-stage HER2-positive (HER2+) breast cancer is always ... Multiple studies show that trastuzumab can dramatically improve survival. In fact, trastuzumab-based treatments for HER2+ breast ...

Background: Variable rates of HER2 protein overexpression ... AOC were centrally screened for HER2 status (243 patients in fi rst line, 77 in relapse). All positive (IHC 3+) and doubtful (IHC ...

HER2-targeted therapies, originally developed for breast cancer, may also benefit patients with rare bile duct cancer and ...

Bile duct cancer is rare, treatment options are limited, and the survival rates are low. The trial also suggests ... have metastatic breast cancer with high levels of HER2 expression (known as ...

Trastuzumab duocarmazine (T-Duo) improved progression-free survival ... 2–positive (HER2+) breast cancer. However, ocular toxicity was prevalent, leading to higher discontinuation rates in ...

"Breast cancer is far too common, and rates are increasing among ... With Timely Receipt of Treatment and Survival Among Patients With HR-Negative, HER2-Positive Breast Cancer, Journal of the ...